ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc. (ONCY) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.9% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.